Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment

Smith, Chelsey J. F.; Friedlander, Sheila Fallon; Gumá, Mónica; Kavanaugh, Arthur; Chambers, Christina D.

doi:10.1002/bdr2.1023

Cited by 110 publications

(103 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, no definitive therapy is available for IH due to the adverse effects of each drug. The risk factors for IH include preterm birth and placental anomalies [ 4 ]. In most cases, IH has a unique clinical course with proliferation and involution phases [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Competitive endogenous RNA networks: integrated analysis of non-coding RNA and mRNA expression profiles in infantile hemangioma

Chen

et al. 2018

Oncotarget

View full text Add to dashboard Cite

Infantile hemangioma (IH) is the most common vascular tumour in infants. The pathogenesis of IH is complex and poorly understood. Therefore, achieving a deeper understanding of IH pathogenesis is of great importance. Here, we used the Ribo-Zero RNA-Seq and HiSeq methods to examine the global expression profiles of protein-coding transcripts and non-coding RNAs, including miRNAs and lncRNAs, in IH and matched normal skin controls. Bioinformatics assessments including gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) pathway analyses were performed. Of the 16370 identified coding transcripts, only 144 were differentially expressed (fold change ≥ 2, P ≤ 0.05), including 84 up-regulated and 60 down-regulated transcripts in the IH samples compared with the matched normal skin controls. Gene ontology analysis of these differentially expressed transcripts revealed 60 genes involved in immune system processes, 62 genes involved in extracellular region regulation, and 35 genes involved in carbohydrate derivative binding. In addition, 256 lncRNAs and 142 miRNAs were found to be differentially expressed. Of these, 177 lncRNAs and 42 miRNAs were up-regulated in IH, whereas 79 lncRNAs and 100 miRNAs were down-regulated. By analysing the Ribo-Zero RNA-Seq data in combination with the matched miRNA profiles, we identified 1256 sponge modulators that participate in 87 miRNA-mediated, 70 lncRNA-mediated and 58 mRNA-mediated interactions. In conclusion, our study uncovered a competitive endogenous RNA (ceRNA) network that could further the understanding of the mechanisms underlying IH development and supply new targets for investigation.

show abstract

Section: Introductionmentioning

confidence: 99%

Competitive endogenous RNA networks: integrated analysis of non-coding RNA and mRNA expression profiles in infantile hemangioma

Chen

et al. 2018

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Infantile hemangiomas (IHs) are the most common benign tumor of infancy 1 – 3 with an incidence of approximately 4–5%. 2 , 4 It is more common in females and Caucasians.…”

Section: Introductionmentioning

confidence: 99%

Current perspectives on the optimal management of infantile hemangioma

Grzesik

2017

PHMT

View full text Add to dashboard Cite

Infantile hemangiomas (IHs) are the most common benign tumor of infancy. As our understanding of their pathobiology has evolved, treatment has become more focused and tailored to specifically treat IH while minimizing adverse effects. Propranolol has gained FDA approval as the first medical therapy for a traditionally surgical disease. This review provides readers with an overview of IH, treatment modalities, and addresses specific considerations in IH disease management.

show abstract

“…Therefore, the choices of therapy approaches are required to find a balance between the effect of antitumor and the efforts to reduce side or adverse reactions. Those over-zealous attempts that to perform aggressively treatments only to pursue a high inhibition rate partially should be avoided [25]. On the other hand, for those infants who were contraindicated to propranolol (contraindication), failed to respond to propranolol (refractory), or hemangiomas regrown after propranolol treatment (recurrence), rapamycin or itraconazole may serve as a choice after comprehensive evaluation.…”

Section: Discussionmentioning

confidence: 99%

Application of the adenosine triphosphate sensitivity assay in infantile vascular anomalies

Yang

et al. 2020

BMC Pediatr

View full text Add to dashboard Cite

Background: The term vascular anomalies include various vascular tumors and vascular malformations, among them infantile hemangiomas and capillary malformations are the most well-known associated diseases in early ages. Multiple drugs have been introduced for intervention, but susceptibility test in vitro were scarcely reported. Objective: To evaluate the inhibition effect of different drugs by adenosine triphosphate sensitivity assay in vitro before the treatment of infantile hemangiomas and capillary malformations. Methods: Specimens were selected from 5 cases of infantile hemangiomas and 11 cases of capillary malformations. Propranolol, rapamycin, sildenafil and itraconazole were tested for their growth inhibition effect by using the adenosine triphosphate sensitivity assay. Results: Propranolol demonstrated inhibitory effects on infantile hemangiomas cells. Rapamycin and itraconazole both showed inhibitory effects on infantile hemangiomas cells and capillary malformations cells. Sildenafil has no growth inhibitory effect on infantile hemangiomas cells or capillary malformations cells. Conclusion: Adenosine triphosphate sensitivity assay is a sensitive and useful testing method before the management of vascular anomalies, and individualized medication suggestions for the choice of therapeutic drugs were offered based on the testing result and together with a comprehensive evaluation of each infant.

show abstract

Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment

Cited by 110 publications

References 49 publications

Competitive endogenous RNA networks: integrated analysis of non-coding RNA and mRNA expression profiles in infantile hemangioma

Competitive endogenous RNA networks: integrated analysis of non-coding RNA and mRNA expression profiles in infantile hemangioma

Current perspectives on the optimal management of infantile hemangioma

Application of the adenosine triphosphate sensitivity assay in infantile vascular anomalies

Contact Info

Product

Resources

About